About: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 18 June 2019

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) artículu científicu espublizáu en xunu de 2019 (ast) scientific article published on 18 June 2019 (en) наукова стаття, опублікована 18 червня 2019 (uk)
publication date	wds:Q92945214-09A38E9E-A832-4303-8BBF-3A0ECA0CC158
publication date	2019-06-18 00:00:00Z (xsd:dateTime)
cites work	wds:Q92945214-14083E63-CDC1-4D36-9AD3-58E884EA8F08 wds:Q92945214-1FA1146D-9B52-424D-8793-1C460B217FF7 wds:Q92945214-2A860A5C-C05D-4114-A803-1385612E6788 wds:Q92945214-4233238A-3927-4D43-AC32-0DBB5047C7DB wds:Q92945214-4C0CBF07-A077-41B5-9043-EF8CBF9BB58D wds:Q92945214-500B4935-C20C-4777-83FB-099917FB4947 wds:Q92945214-5EF3C175-E72D-4495-9898-E5A19511EE96 wds:Q92945214-630AB3E7-A04B-4279-8733-35552EF9F1B3 wds:Q92945214-64A555FB-71D5-4E1F-9AD2-2C69F4D88948 wds:Q92945214-69D9C054-E3B0-455B-AA99-1F0401F163E7 wds:Q92945214-75AA9D3E-6401-4AEC-9E8A-24FF2C1F9BD8 wds:Q92945214-83FDDB88-5511-4ED4-85E8-E729609B4A17 wds:Q92945214-86776949-104B-495A-855C-7E3A67677FBA wds:Q92945214-8B7A8037-518F-4CEE-BCF3-AD2784046A58 wds:Q92945214-9CAD46FB-D894-4766-93A3-F9A4A088A3E7 wds:Q92945214-BB0FD50A-4A84-40E1-9716-09F4DE158362 wds:Q92945214-C604DB63-FE79-4F24-9EDD-E874314A8ABF wds:Q92945214-C8684AFA-A235-4C81-B1AE-E68B2F36FEB8 wds:Q92945214-CE2E4761-54EF-42A3-BC24-008E47670E9D wds:Q92945214-D29D7B68-FF13-4BDF-AB21-3F48416FAFAB wds:Q92945214-DC924F72-1452-48F9-9EA4-81420CD420CC wds:Q92945214-E6B18715-C086-4D89-958D-6974905C5DC6 wds:Q92945214-ECD90EF6-8A7C-4D32-B62A-52FB9225B9F6 wds:Q92945214-F04511FD-4A6B-4860-816E-8124D6B5BFFB
cites work	Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Tables of the number of patients required in clinical trials using the logrank test. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. High-precision conformal radiotherapy (HPCRT) of prostate cancer--a new technique for exact positioning of the prostate at the time of treatment Fractionation and late rectal toxicity Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials Cancer statistics, 2018. Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials Validation of the intestinal part of the prostate cancer questionnaire "QUFW94": psychometric properties, responsiveness, and content validity Making Radiation Therapy for Prostate Cancer More Economical and More Convenient The linear quadratic model: usage, interpretation and challenges
author name string	wds:Q92945214-01F65829-01D4-4692-B1F3-FADA87C85561 wds:Q92945214-01FEDF33-F96B-4200-AEBF-B523CEB7DF54 wds:Q92945214-05489E68-777D-4FC8-B8F0-A8A3724C1C39 wds:Q92945214-0DF5BC94-C637-4626-BD84-9E1D189514DA wds:Q92945214-1D620352-1304-4112-8A1E-4AF384D18D9E wds:Q92945214-6827DD91-1679-46D5-88D6-608BA81FB2DA wds:Q92945214-7197EACB-941D-4EAF-8CFB-8702B1768066 wds:Q92945214-7A2FEC0D-72F7-475B-8D75-1BD40339C581 wds:Q92945214-836FF2B7-B07A-4E9B-9140-F9B521133058 wds:Q92945214-8838BE34-3F38-4116-8584-76C1088E97CC wds:Q92945214-8E208675-679A-4B93-9F6C-C5C35E1C185F wds:Q92945214-9324FA09-090D-492C-A236-E83E428E3839 wds:Q92945214-942C897D-E833-446C-A237-0FA4DCBB8990 wds:Q92945214-9AF68131-5746-444C-81E3-B9BBBCE044CC wds:Q92945214-9F6664BB-F0C4-43CE-96FC-24072045E37B wds:Q92945214-B17881A0-4F52-4231-AE96-CE5384811B06 wds:Q92945214-B3031295-164D-41AE-95D1-1F53BD830217 wds:Q92945214-CADE41B5-C730-4158-A370-8ED35A75E41D wds:Q92945214-D7ED0B63-2F73-4114-A17D-9F01CCE7FCC9 wds:Q92945214-F70A1500-DD37-4866-A429-BC37E8E7349A
author name string	David Norman Bengt Johansson Per Fransson Harald Anderson Björn Tavelin Lars Franzén Elisabeth Kjellén Björn Zackrisson Anders Widmark Adalsteinn Gunnlaugsson Per Nilsson Morten Hoyer Jon Kindblom Lars Beckman Måns Agrup Claes Ginman Camilla Thellenberg-Karlsson Magnus Lagerlund Kirsten Björnlinger Mihajl Seke
rdfs:label	Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial (en) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial (nl)
skos:prefLabel	Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial (en) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial (nl)
name	Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial (en)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software